Key facts
- Notable investors include iAngels, Rhodium, TAU Ventures (Israel).
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Per.Me
- ·The full record, as it builds
Funding rounds
No funding rounds for Per.Me are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Per.Me
Developer of a deep-tech digital health platform designed for DNA testing. The company's platform specializes in creating a digital DNA report that can be used to tailor healthcare services and product recommendations to an individual's unique genetic makeup, enabling clients to personalize preventative care and product recommendations through a user-friendly and affordable DNA profiling test.
- Sector
- Healthcare
- HQ
- Herzliya, Israel
- Founded
- 2022
- Employees
- 14
- Website
- permedna.com/
- Ownership
- Privately Held (backing)
Per.Me doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Per.Me shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Per.Me in its N-PORT filings yet. We sweep new filings monthly.